BRPI0916191A2 - Formas sólidas de (2s, 3r, 4r, 5s, 6r) -2-(4-cloro -3-(4-etoxibenzil) fenil) -6-(metiltio) tetra-hidro-2h-piran -3,4,5- triol e métodos de seu uso - Google Patents

Formas sólidas de (2s, 3r, 4r, 5s, 6r) -2-(4-cloro -3-(4-etoxibenzil) fenil) -6-(metiltio) tetra-hidro-2h-piran -3,4,5- triol e métodos de seu uso

Info

Publication number
BRPI0916191A2
BRPI0916191A2 BRPI0916191A BRPI0916191A BRPI0916191A2 BR PI0916191 A2 BRPI0916191 A2 BR PI0916191A2 BR PI0916191 A BRPI0916191 A BR PI0916191A BR PI0916191 A BRPI0916191 A BR PI0916191A BR PI0916191 A2 BRPI0916191 A2 BR PI0916191A2
Authority
BR
Brazil
Prior art keywords
ethoxybenzyl
triol
tetrahydro
chloro
phenyl
Prior art date
Application number
BRPI0916191A
Other languages
English (en)
Inventor
Margaret De Paul Susan
Mangzhu Zhao Matthew
Perlberg Anett
Original Assignee
Lexicon Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Phamaceuticals Inc filed Critical Lexicon Phamaceuticals Inc
Publication of BRPI0916191A2 publication Critical patent/BRPI0916191A2/pt
Publication of BRPI0916191B1 publication Critical patent/BRPI0916191B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

FORMAS SÓLIDAS DE (2S,3R,4R,5S,6R)-2-(4-CLORO-3-(4-ETOXIBENZIL)FENIL)-6-(METlLTIO)TETRA-HlDRO-2H-PIRAN-3,4,5-TRIOL E MÉTODOS DE SEU USO. A presente invenção refere-se às formas sólidas de (2S,3R,4R,5S,6R)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metíltio)tetra-hidro-2H-piran-3,4,5-triol anidro, além dos métodos para seu uso no tratamento de várias doenças e distúrbios.
BRPI0916191-0A 2008-07-17 2009-07-15 Formas sólidas de (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4- etoxibenzil)fenil)-6- (metiltio)tetra-hidro-2h-piran-3,4,5- triol e seus usos BRPI0916191B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17
US61/081,423 2008-07-17
PCT/US2009/050636 WO2010009197A1 (en) 2008-07-17 2009-07-15 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use

Publications (2)

Publication Number Publication Date
BRPI0916191A2 true BRPI0916191A2 (pt) 2017-08-29
BRPI0916191B1 BRPI0916191B1 (pt) 2025-12-09

Family

ID=

Also Published As

Publication number Publication date
HK1243713A1 (zh) 2018-07-20
TW201006808A (en) 2010-02-16
EP2332947B1 (en) 2017-11-01
KR20110031196A (ko) 2011-03-24
JP2016041701A (ja) 2016-03-31
UY31992A (es) 2010-02-26
AU2009270973B2 (en) 2014-01-30
SG185317A1 (en) 2012-11-29
WO2010009197A1 (en) 2010-01-21
CL2009001595A1 (es) 2010-07-19
RU2011105797A (ru) 2012-08-27
IL210269A (en) 2015-06-30
KR20170010069A (ko) 2017-01-25
PL2332947T3 (pl) 2018-04-30
UA106048C2 (uk) 2014-07-25
CA2730931A1 (en) 2010-01-21
AR072807A1 (es) 2010-09-22
HUE035400T2 (en) 2018-05-02
DK2332947T3 (da) 2018-01-29
NO2332947T3 (pt) 2018-03-31
ZA201100175B (en) 2012-03-28
CN107629097A (zh) 2018-01-26
NZ590184A (en) 2012-09-28
AU2009270973A1 (en) 2010-01-21
CO6351797A2 (es) 2011-12-20
US9067962B2 (en) 2015-06-30
US20100016422A1 (en) 2010-01-21
JP6283337B2 (ja) 2018-02-21
US8217156B2 (en) 2012-07-10
MX2011000503A (es) 2011-03-01
RU2505543C2 (ru) 2014-01-27
IL210269A0 (en) 2011-03-31
CN102112483A (zh) 2011-06-29
US20130165395A1 (en) 2013-06-27
KR101707246B1 (ko) 2017-02-15
ES2656357T3 (es) 2018-02-26
EP2332947A1 (en) 2011-06-15
JP2011528366A (ja) 2011-11-17
PE20100260A1 (es) 2010-04-16
PT2332947T (pt) 2018-02-06
TWI472521B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
UY31992A (es) Formas sólidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetrahidro-2h-pirano-3,4,5-triol y métodos para su uso
CY1119810T1 (el) Παραγωγα(2s,3r,4r,5s,6r)-2-(4-χλωρο-3-βενζυλφαινυλ)-6-(υδροξυμεθυλ)τετραϋδρο-2h-πυραν-3,4,5-τριολης για χρηση στη θεραπεια του διαβητη
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
UA111199C2 (uk) Співкристали l-проліну і лимонної кислоти з (2s,3r,4r,5s,6r)-2-(3-((5-(4-фторфеніл)тіофен-2-іл)метил)-4-метилфеніл)-6-(гідроксиметил)тетрагідро-2h-піран-3,4,5-тріолом
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
PL2661256T3 (pl) Kompozycje zawierające (2S,3R,4R,5S,6R)-2-(4-chloro-3)-(4-etoksybenzylo)fenylo)-6-(metylotio)tetrahydro-2H-pirano-3,4,5-triol
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201590748A1 (ru) Противовирусные соединения против rsv
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
DK1937669T3 (da) Nye benzopyranderivater som kaliumkanalåbnere
EA200702253A1 (ru) Фармацевтическая композиция
BRPI0606974A2 (pt) uso de compostos de complexo de ferro(iii)
EA200800780A1 (ru) Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq
WO2011004175A3 (en) Viscous topical antimicrobial compositions
HN2007000505A (es) Analogos de pirazol
WO2012173410A3 (en) Novel c-aryl ansa sglt2 inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.